Acquired ROS1 Fusion and Iruplinalkib Response in Advanced NSCLC after Multiple Lines of Systematic Therapy: A Case Report

Jiarui Liu¹Zhichao Jiao¹Jun Zhou²Yuan Yuan²Qiguang Li²Wei Zhou²Shuai Zhang²Shuping Yang^2*

• ¹Shandong First Medical University, Tai'an, China
• ²Shandong Provincial Hospital, Jinan, Shandong Province, China

This is the first report of a patient with lung cancer whose primary focus was the upper lobe of the left lung combined with multiple metastases in both lungs, initially diagnosed as a non-driver gene mutation, who subsequently developed SDC4-ROS1 fusion after multiple lines of systemic therapy. When diagnosis, a needle biopsy of the primary focus revealed no driver gene mutation and low PD-L1 expression (TPS < 1%, CPS 3). From November 2022 to December 2023, the patient received sequential chemotherapy-based systemic therapy including anti-angiogenesis treatment, concurrent chemoradiation and combined immunotherapy as determined by the clinician based on the initial evaluation. In December 2023, a needle biopsy of a metastasis in the left lower lobe of the lung showed a positive SDC4-ROS1 fusion. Subsequent treatment with the oral ALK TKI iruplinalkib was initiated based on the patient's preference, which exhibited a promising response over the next 2 months.